Core Viewpoint - The company has completed the investment project of the "Semiconductor Testing and Intelligent Manufacturing Equipment Industrial Park" and plans to permanently supplement its working capital with the remaining raised funds, following the completion of the project and the approval of the board and shareholders [6][9][10]. Fundraising Overview - The company raised a total of RMB 758.8 million from its initial public offering, with a net amount of RMB 689.55 million after deducting issuance costs [1]. - The company established a special account for the management and use of the raised funds, ensuring compliance with regulatory requirements [2]. Investment Project Details - The company committed to invest RMB 276.46 million in the "High-Precision Small Power Testing Power Supply and Fuel Cell, Power Semiconductor Testing Equipment Production Base Construction Project" [2]. - The actual net amount raised was RMB 689.55 million, resulting in an excess of RMB 413.09 million after the planned investment [3]. Use of Excess Funds - The company decided to use RMB 120 million of the excess funds to permanently supplement working capital, which constitutes approximately 29.05% of the total excess funds [3][4]. - The remaining excess funds will be allocated to the "Semiconductor Testing and Intelligent Manufacturing Equipment Industrial Park Project," with a total investment of RMB 450 million, of which RMB 300 million will come from excess funds [4][5]. Project Completion and Surplus Funds - As of July 31, 2025, the project has completed its main construction and acceptance work, leading to the decision to conclude the project [6]. - The expected surplus funds amount to RMB 168.27 million, which includes interest and investment income, and will be used to permanently supplement working capital [8][9]. Impact on Company Operations - The decision to conclude the project and use surplus funds for working capital is aligned with the company's operational needs and long-term development strategy, enhancing cash flow and resource allocation [9][10]. - The company will maintain the special account for raised funds until all pending payments are settled, ensuring compliance with regulatory requirements [9]. Approval Process - The board of directors approved the proposal to conclude the investment project and use surplus funds on August 22, 2025, which will also require shareholder approval [10]. - The sponsor institution has confirmed that the decision complies with relevant regulations and is in the best interest of all shareholders [10][11].

Core Viewpoint - The company has decided to extend the implementation period for certain fundraising investment projects to optimize resource allocation and improve the efficiency of fundraising usage, aligning with its long-term development strategy [5]. Group 1: Fundraising Project Overview - The company raised a total of RMB 276,849.25 million through its initial public offering, with a share price of RMB 50.88 per share for 60 million shares [1]. - The total investment for the fundraising projects is RMB 778,506,100, with the company having excess funds of RMB 198,998.64 million after accounting for project needs [2]. Group 2: Extension of Implementation Period - The company plans to extend the implementation period for the "Information Management System Construction Project" from October 28, 2025, to December 31, 2027, to meet growing business needs and enhance patient experience [4]. - The project involves a total investment of RMB 20,386.80 million, fully funded by the raised capital, and includes components such as remote consultation systems and electronic medical records [4]. Group 3: Impact of the Extension - The decision to extend the project timeline is based on the company's future development plans and the actual progress of the fundraising projects, ensuring no adverse effects on project implementation or shareholder interests [5]. - The extension does not involve changes to the total investment amount, the amount of raised funds allocated, or the implementation methods of the projects [5]. Group 4: Decision-Making Process and Verification - The board of directors and the supervisory board approved the extension on August 21, 2025, within the board's authority, eliminating the need for shareholder approval [5]. - The sponsoring institution has verified that the extension complies with relevant regulations and does not alter the intended use of the raised funds [5].

Meeting Overview - The board meeting of Yingkang Life Technology Co., Ltd. was held on August 12, 2025, via telephone and email, with all 9 directors present and voting [1] - The meeting was chaired by Ms. Tan Lixia, and the company's senior management attended [1] Financial Report Approval - The board unanimously approved the company's 2025 semi-annual report, confirming it accurately reflects the financial status and operational results for the first half of 2025, with no false records or misleading statements [1][2] - The voting results for this agenda item were 9 votes in favor, 0 against, and 0 abstentions [2] Fund Usage Report - The board approved a special report on the storage and usage of raised funds for the first half of 2025, confirming compliance with relevant regulations and no misuse of funds [2] - The voting results for this agenda item were also 9 votes in favor, 0 against, and 0 abstentions [2] Cash Management Proposal - The board approved the use of up to RMB 300 million of idle self-owned funds for cash management, aiming to enhance fund efficiency and reduce financial costs, with a validity period of 12 months [3] - The board authorized the general manager to make investment decisions within the approved limits [3] - The voting results for this agenda item were 9 votes in favor, 0 against, and 0 abstentions [3]

格林美股份有限公司 募集资金管理办法（草案） （H 股发行并上市后适用） 第一章 总 则 第一条 为规范格林美股份有限公司（以下简称"公司"）募集资金的存放、 使用和管理，保证募集资金的安全，提高募集资金的使用效率，根据《中华人民 共和国公司法》、《中华人民共和国证券法》、《上市公司募集资金监管规则》、 《深圳证券交易所股票上市规则》、《深圳证券交易所上市公司自律监管指引第 下简称"《香港联交所上市规则》"）等法律、法规及规范性文件的规定，制定 本办法。 第二条 本办法所称募集资金，是指公司通过发行股票或者其他具有股权性 质的证券，向投资者募集并用于特定用途的资金，但不包括公司为实施股权激励 计划募集的资金监管。 公司在香港证券市场通过发行 H 股募集资金管理按《香港联交所上市规 则》的相关规定执行。 第三条 募集资金到位后，公司应及时办理验资手续，由符合《证券法》规 定的会计师事务所出具验资报告。公司对募集资金的管理遵循专户存放、规范使 用、如实披露、严格管理的原则。 第四条 募集资金只能用于公司对外公布的募集资金投向的项目。公司董事 会应制定详细的资金使用计划，做到资金使用的规范公开和透明。 第五条 非经 ...

格林美股份有限公司 第一章 总 则 第一条 为规范格林美股份有限公司（以下简称"公司"）募集资金的存放、 使用和管理，保证募集资金的安全，提高募集资金的使用效率，根据《中华人民 共和国公司法》、《中华人民共和国证券法》、《上市公司募集资金监管规则》、 《深圳证券交易所股票上市规则》、《深圳证券交易所上市公司自律监管指引第 第二条 本办法所称募集资金，是指公司通过发行股票或者其他具有股权性 质的证券，向投资者募集并用于特定用途的资金，但不包括公司为实施股权激励 计划募集的资金监管。 第三条 募集资金到位后，公司应及时办理验资手续，由符合《证券法》规 定的会计师事务所出具验资报告。公司对募集资金的管理遵循专户存放、规范使 用、如实披露、严格管理的原则。 第四条 募集资金只能用于公司对外公布的募集资金投向的项目。公司董事 会应制定详细的资金使用计划，做到资金使用的规范公开和透明。 第五条 非经公司股东会作出有效决议，任何人无权改变发行申请文件中承 诺的募集资金使用用途。 第六条 公司董事会应建立健全公司的募集资金管理制度并确保本制度的有 效实施，及时披露募集资金的使用情况，做到募集资金使用的公开、透明和规范。 第七 ...

Core Viewpoint - ST Dongshi (603377) has received an administrative regulatory decision from the Beijing Securities Regulatory Bureau, prompting the company to implement a comprehensive rectification plan to address identified issues [1][4]. Summary by Sections Regulatory Violations - On April 18, 2024, the company approved the temporary use of 106 million yuan of idle raised funds to supplement working capital for 12 months. However, due to multiple litigation cases and significant liquidity pressure, the company failed to repay the funds by the due date of April 17, 2025, violating relevant regulations [2]. Rectification Measures - The company is taking a multi-faceted approach to rectify the situation, including: - Accelerating communication with banks for new credit and extension plans - Liquidating inefficient idle assets and disposing of non-core fixed assets - Optimizing cash flow management and reducing expenses - Ensuring the repayment of 387 million yuan of non-operating funds by controlling shareholders and related parties - Actively seeking resolution with creditors through judicial mediation and negotiation - Hiring a professional legal team to manage long-standing or disputed debts [3]. Responsibility and Management - The rectification responsibility lies with the Chairman, General Manager, and Chief Financial Officer, with the board enforcing accountability for timely and effective rectification measures. The company asserts that the regulatory decision will not impact normal operations and emphasizes the importance of learning from this experience to protect the interests of the company and its investors [4].

Core Points - The company has approved a cash dividend distribution plan for the year 2024, proposing to distribute RMB 3.00 per 10 shares, totaling approximately RMB 32.97 million [3][4] - The company will use RMB 176.58 million of remaining raised funds to permanently supplement working capital, which accounts for 24.48% of the total raised funds [4][5] - The company has approved an increase in capital of RMB 20 million to its subsidiary, Dongguan Weikang Automotive Electronics Co., Ltd. [8] - The company has revised its articles of association and completed the necessary business registration changes [9] - The company has estimated that the total amount of daily related transactions with Dongguan Weifeng Interconnect Technology Co., Ltd. for 2025 will not exceed RMB 9.12 million [10] Financial Data - The company plans to distribute cash dividends based on a total share capital of 109,893,594 shares [3] - The cash dividend distribution for 2024 is expected to be completed by May 29, 2025 [4] - The company has adjusted the expected completion date for a project funded by raised funds from June 30, 2025, to September 30, 2025 [6] - The company has approved the use of up to RMB 700 million of idle self-owned funds for entrusted wealth management within a 12-month period [7]

Core Viewpoint - The company has approved the use of its own funds to pay for part of the investment project costs, which will later be replaced with raised funds, ensuring compliance with regulations and maintaining operational efficiency [23][29][31]. Group 1: Company Overview - The company is named Haishike Pharmaceutical Group Co., Ltd. and is publicly traded with the stock code 002653 [10]. - The company held its fifth board meeting on August 22, 2025, where all directors attended and approved the half-year report [2][5]. Group 2: Financial Data - The company raised a total of RMB 800 million through a non-public stock issuance, with a net amount of RMB 790.87 million after deducting issuance costs [11][23]. - The company has established a special account for the management of raised funds, ensuring compliance with regulatory requirements [12][23]. Group 3: Fund Usage - The company plans to use surplus funds from previous projects for new initiatives, including RMB 16.42 million for working capital and RMB 53.02 million for clinical research projects [25]. - The company has not changed the implementation location or method for any investment projects during the reporting period [14]. Group 4: Fund Management - The company has implemented a cash management strategy for temporarily idle raised funds, generating a cash return of RMB 1.39 million during the reporting period [15]. - The company has established a process for replacing its own funds with raised funds within six months, ensuring that the funds are used effectively [27][28]. Group 5: Compliance and Oversight - The board of directors has ensured that the use of self-funds for project payments complies with relevant regulations and does not affect the project's implementation [29][31]. - The company has received no negative feedback from its sponsor regarding the fund management practices [31].

Group 1 - The company did not distribute cash dividends or bonus shares during the reporting period [3] - The company has not changed its controlling shareholder or actual controller during the reporting period [5][6] - The company has established a fundraising management system to ensure the proper use of raised funds [14][15] Group 2 - The company raised a total of RMB 569,999,999.18 through a specific stock issuance, with a net amount of RMB 555,529,176.74 after deducting issuance costs [9][55] - As of June 30, 2025, the company had used RMB 27,353.29 million for investment contracts related to its fundraising projects, accounting for 54.06% of the total investment [56] - The company plans to extend the expected usable status date of its fundraising project to December 31, 2027, due to delays in project implementation [55][57] Group 3 - The company reported an asset impairment loss of RMB 6,433,740.81 for the first half of 2025, which will reduce the total profit for that period [46][51] - The company has complied with all relevant regulations regarding the management and use of raised funds, with no violations reported [25][61] - The company has received approval from its board and supervisory committee for the extension of its fundraising project timeline, ensuring it aligns with the company's long-term development goals [58][60]

Core Viewpoint - The company has conducted its second board meeting to discuss and approve various financial reports and management proposals, including the use of idle funds for cash management and the evaluation of risk assessments related to its financial subsidiary. Group 1: Board Meeting Details - The second board meeting of the company was held on August 21, 2025, with all nine directors present, and the meeting was conducted in accordance with legal and regulatory requirements [8][11]. - The board approved the special report on the use of raised funds for the first half of 2025, which complies with relevant regulations [9][10]. Group 2: Financial Management and Reports - The company plans to use up to RMB 220 million of temporarily idle raised funds and RMB 70 million of idle self-owned funds for cash management, ensuring that normal operations and risk controls are maintained [12][14]. - The total amount raised from the initial public offering was RMB 2.87 billion, with a net amount of RMB 2.80 billion after deducting issuance costs [30][47]. - As of June 30, 2025, the balance of the raised funds was RMB 2.15 billion, with specific usage details provided in the report [31][33]. Group 3: Risk Assessment and Governance - The board approved a risk assessment report for the company's financial subsidiary, ensuring that the evaluation of operational qualifications and internal controls was thorough [12][14]. - The company has established a management framework for raised funds, adhering to legal and regulatory standards to prevent misuse [41][62]. Group 4: Upcoming Shareholder Meeting - The company will hold its third extraordinary general meeting on September 10, 2025, allowing for both on-site and online voting [70][72]. - The meeting will address various proposals that have been previously approved by the board and supervisory committee [72][74].